A Century After the Description of “Hormones”, Our Golden Jubilee Celebration Goes on with What is New in Endocrine Oncology: And a Lot is New!

About 3000 thousand years ago Marcus Aurelius said: “Time is a sort of river of passing events, and strong is its current; no sooner is a thing brought to sight than it is swept by and another takes its place, and this too will be swept away…” [1].

Publication History

Received: 13 July 2020

Accepted: 13 July 2020

Article published online:
13 August 2020

• References

• 1 Marcus Aurelius. Meditations. Tanslated by Hays G New York, NY: Modern Library; (paperback edition) 2003
• 2 Stratakis CA. Pheochromocytomas: Fabulous, fascinating, and first (in everything)!. Horm Metab Res 2019; 51: 401-402
• 3 Stratakis CA. Medical treatment of pituitary adenomas: A celebration of endocrinology (and oncology)!. Horm Metab Res 2020; 52: 7
• 4 Roth J, Qureshi S, Whitford I. et al. Insulin’s discovery: New insights on its ninetieth birthday. Diabetes Metab Res Rev 2012; 28: 293-304
• 5 Modlin IM, Kidd M. Ernest Starling and the discovery of secretin. J Clin Gastroenterol 2001; 32: 187-192
• 6 Vasilev V, Daly AF, Zacharieva S. et al. Clinical and molecular update on genetic causes of pituitary adenomas. Horm Metab Res 2020; 52: 553-561
• 7 Chahal HS, Stals K, Unterländer M. et al. AIP mutation in pituitary adenomas in the 18^th century and today. N Engl J Med 2011; 364: 43-50
• 8 de Herder WW. The history of acromegaly. Neuroendocrinology 2016; 103: 7-17
• 9 Markantes GK, Theodoropoulou A, Armeni AK. et al. Cyclopes and Giants: From Homer’s Odyssey to contemporary genetic diagnosis. Hormones (Athens) 2016; 15: 459-463
• 10 Gheorghiu ML, Negreanu F, Fleseriu M. Updates in the medical treatment of pituitary adenomas. Horm Metab Res 2020; 52: 8-24
• 11 Araque KA, Gubbi S, Klubo-Gwiezdzinska J. Updates on the management of thyroid cancer. Horm Metab Res 2020; 52: 562-577
• 12 Simonds WF. Clinical and molecular genetics of primary hyperparathyroidism. Horm Metab Res 2020; 52: 578-587
• 13 Ilanchezhian M, Khan S, Okafor S. et al. Update on the treatment of medullary thyroid carcinoma in patients with multiple endocrine neoplasia type 2. Horm Metab Res 2020; 52: 588-597
• 14 Berthon A, Bertherat J. Update of genetic and molecular causes of adrenocortical hyperplasias causing Cushing syndrome. Horm Metab Res 2020; 52: 598-606
• 15 Plaska SW, Liu C-J, Lim JS. et al. Targeted RNAseq of formalin-fixed paraffin-embedded tissue to differentiate among benign and malignant adrenal cortical tumors. Horm Metab Res 2020; 52: 607-613
• 16 Tsoli M, Alexandraki K, Xanthopoulos C. et al. Medical treatment of gastrointestinal neuroendocrine neoplasms. Horm Metab Res 2020; 52: 614-620
• 17 Melmed S. Acromegaly, “Section 8 The Endocrine System”. In: Rakel RE Ed. Conn’s Current Therapy. Philadelphia: W. B. Saunders; 1991: 565–568
• 18 Kamilaris CT, Chrousos GP. Cushing’s Syndrome, “Section 8 The Endocrine System”. In: Rakel RE, Ed. Conn’s Current Therapy. Philadelphia: W. B. Saunders; 1991: 572–578
• 19 Nankova A, Yaneva M, Elenkova A. et al. Cushing’s syndrome: A historic review of the treatment strategies and corresponding outcomes in a single tertiary center over the past half-century. Horm Metab Res 2018; 50: 280-289
• 20 Afshari A, Keil M, Lyssikatos C. et al. Optical imaging technology: A useful tool to identify remission in cushing disease after surgery. Horm Metab Res 2019; 51: 120-126 ; Correction: Horm Metab Res 2019; 51: e1
• 21 Petersenn S. Management of aggressive pituitary tumors – A 2019 update. Horm Metab Res 2019; 51: 755-764
• 22 Crouzeix G, Morello R, Thariat J. et al. Quality of life but not cognition is impacted by radiotherapy in patients with non-functioning pituitary adenoma. Horm Metab Res 2019; 51: 178-185
• 23 Daskalakis K, Tsoli M, Alexandraki K. et al. Magnetic resonance imaging or endoscopic ultrasonography for detection and surveillance of pancreatic neuroendocrine neoplasms in patients with multiple endocrine neoplasia type 1?. Horm Metab Res 2019; 51: 580-585
• 24 Nagayama Y. Thyroid autoimmunity and thyroid cancer – the pathogenic connection: A 2018 update. Horm Metab Res 2018; 50: 922-931
• 25 Tsoli M, Alexandraki KI, Spei M-E. Anti-tumor activity and safety of multikinase inhibitors in advanced and/or metastatic thyroid cancer: a systematic review and network meta-analysis of randomized controlled trials. Horm Metab Res 2020; 52: 25-31
• 26 Du Q, Yao D-S, Wang Y-W. Research progress on lncRNA functions and mechanisms in pituitary adenomas. Horm Metab Res 2020; 52: 280-288